Metastasis News and Research

RSS

Metastasis is the spread of cancer from one part of the body to another. A tumor formed by cells that have spread is called a “metastatic tumor” or a “metastasis.” The metastatic tumor contains cells that are like those in the original (primary) tumor. The plural form of metastasis is metastases

Certain colon cancer genes take a step back to move forward

Recent Weizmann Institute studies are revealing a complex picture of cancer progression in which certain genes that drive tumor growth in the earlier stages get suppressed in later stages - taking a step back to move forward.

1 Jul 2015

Breast tumors have something in common with embryos, say MD Anderson researchers

It may seem incredulous, but breast tumors may have something in common with embryos ... at least in mice, say researchers at The University of Texas MD Anderson Cancer Center.

1 Jul 2015

UCSD researchers discover cell signaling pathway that controls initiation, progression of colorectal cancer

Researchers at University of California, San Diego School of Medicine have discovered a cell signaling pathway that appears to exert some control over initiation and progression of colorectal cancer, the third leading cause of cancer-related death in the United States. A key protein in the pathway also appears to be predictive of cancer survival rates.

1 Jul 2015

Researchers map physical properties of live breast cancer cells using advanced AFM technology

Researchers who developed a high-speed form of atomic force microscopy have shown how to image the physical properties of live breast cancer cells, for the first time revealing details about how deactivation of a key protein may lead to metastasis.

30 Jun 2015

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

The enzyme phosphatidylinositol-3 kinase (PI3K) appears to be exploited in almost every type of human cancer, making it the focus of considerable interest as a therapeutic target, with many PI3K-inhibiting drugs currently in various stages of clinical development. However, PI3K inhibitors have only shown modest clinical activity with patients who receive these drugs experiencing very little improvement in survival.

30 Jun 2015

Researchers identify better way to screen for lung cancer

The Valley Hospital in Ridgewood, NJ, is pleased to announce that two of its oncologists and a research scientist are helping pave the way to an easier, more accurate, less invasive way to screen for the most common form of lung cancer. Lung cancer is the most common cancer in men worldwide and the number one cancer killer in the United States.

30 Jun 2015

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

With more than 800,000 new cases of cancer among women in the United States expected this year, according to the American Cancer Society, almost everyone is touched by the disease.

27 Jun 2015

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

In research published in Cancer Cell, Thomas Burris, Ph.D., chair of pharmacology and physiology at Saint Louis University, has, for the first time, found a way to stop cancer cell growth by targeting the Warburg Effect, a trait of cancer cell metabolism that scientists have been eager to exploit.

26 Jun 2015

Caltech chemists develop new sensitive technique that can detect colorectal cancer in tissue samples

Chemists at Caltech have developed a new sensitive technique capable of detecting colorectal cancer in tissue samples -- a method that could one day be used in clinical settings for the early diagnosis of colorectal cancer.

26 Jun 2015

Growth of lymph node metastases takes advantage of existing blood vessels

While the use of antiangiogenesis drugs that block the growth of new blood vessels can improve the treatment of some cancers, clinical trials of their ability to prevent the development of new metastases have failed. Now a study from the Massachusetts General Hospital Cancer Center may have found at least one reason why.

26 Jun 2015

International study provides evidence of clear link between smoking and risk of prostate cancer

Smoking is a known risk factor for the development of various forms of cancer. However, when it comes to the link between smoking and prostate cancer, the findings of previous studies have been contradictory. Now, for the first time, an international study led by MedUni Vienna and Basle University Hospital, has provided evidence of a clear link.

22 Jun 2015

Scientists identify two new key players involved in development of prostate cancer

Understanding how a normal healthy cell turns into a cancerous one is our best bet yet for beating the disease. It will help better diagnose the cancer type, and enable the development of more effective, and less toxic therapies. But cells have evolved all sorts of sophisticated ways to become cancerous, and identifying the molecules involved and how they function in each type of cancer is a major undertaking.

16 Jun 2015

Study explores role of ALK1 protein in breast cancer metastasis

Pietras said that although prognosis for breast cancer is relatively good when detected in its early stages, metastatic disease is the cause of 90 percent of all cancer-related deaths. Therefore, learning more about the metastatic process and finding new cures to inhibit disease spread is at the center of clinical attention.

15 Jun 2015

Researchers identify gene variant that makes breast cancer cells more aggressive

A particular human gene variant makes breast cancer cells more aggressive. Not only are these more resistant to chemotherapy but also leave the primary tumour and establish themselves in other parts of the body in the form of metastases. An international group of researchers led by Lukas Kenner of MedUni Vienna has now identified a gene, AF1q, as being substantially responsible for this and recognized it as a possible starting point for more accurate diagnosis and potential targeted therapeutic approaches.

15 Jun 2015

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

Sentinel node biopsy is the standard staging procedure for melanoma patients, and sentinel node status is the most important prognostic factor for disease outcome in AJCC stage I/II disease. However, the therapeutic value of the sentinel node procedure followed by early completion lymph node dissection is still controversial.

15 Jun 2015

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

USC Stem Cell researcher Min Yu, MD, PhD, is one of five early-career scientists to be named a 2015 Pew-Stewart scholar for cancer research. As part of this honor, she will receive $240,000 over four years to advance the understanding of metastatic breast cancer.

11 Jun 2015

Experts examine latest evidence-based medicine in treating metastatic brain and spinal cancer

Experts from around the country will join faculty experts from the University of Louisville's James Graham Brown Cancer Center, a part of KentuckyOne Health, to look at the latest evidence-based medicine in treating metastatic cancer of the central nervous system.

11 Jun 2015

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

OncoGenex Pharmaceuticals, Inc. announced today that the U.S. Food and Drug Administration (FDA) has agreed to the Company's proposed amendment to the Phase 3 AFFINITY protocol and statistical analysis plan.

10 Jun 2015

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

BerGenBio AS, an oncology biopharmaceutical company, today announces that its multi-centre open label Phase 1b trial (BGBC004) of BGB324, a selective inhibitor of Axl, in patients with Stage IIIb and Stage IV non-small cell lung cancer (NSCLC) in erlotinib-sensitive and refractory patients who have an activating EGFR mutation, is now underway at the University of Texas MD Anderson Cancer Center, Houston, Oncology Partners, Houston, and at UT Southwestern Medical Center, Dallas, Texas, USA.

10 Jun 2015

Researchers identify immune system marker that drives therapy-resistant prostate cancer

You are a patient who has just been treated for a serious illness but neither you nor your doctor knows how likely it is that you -- in comparison with other patients -- will actually be helped by the treatment. This is often the situation with prostate cancer, one of the deadliest and most highly prevalent cancers. While hormone therapy can help, patient responses vary widely, and it's still unclear why some types of prostate cancer seem to be resistant to the therapy.

5 Jun 2015

Metastasis News and Research

Further Reading

Certain colon cancer genes take a step back to move forward

Breast tumors have something in common with embryos, say MD Anderson researchers

UCSD researchers discover cell signaling pathway that controls initiation, progression of colorectal cancer

Researchers map physical properties of live breast cancer cells using advanced AFM technology

Wistar Institute study shows that PI3K inhibitors may make a patient's cancer even worse

Researchers identify better way to screen for lung cancer

The Mary Kay Foundation awards $1.3 million grant to advance cancer research and discovery

SLU researchers find way to stop growth of cancer cells by targeting the Warburg Effect

Caltech chemists develop new sensitive technique that can detect colorectal cancer in tissue samples

Growth of lymph node metastases takes advantage of existing blood vessels

International study provides evidence of clear link between smoking and risk of prostate cancer

Scientists identify two new key players involved in development of prostate cancer

Study explores role of ALK1 protein in breast cancer metastasis

Researchers identify gene variant that makes breast cancer cells more aggressive

EORTC prospective registry targets patients with minimal sentinel node tumor burden in melanoma

USC Stem Cell scientist named 2015 Pew-Stewart scholar for cancer research

Experts examine latest evidence-based medicine in treating metastatic brain and spinal cancer

FDA agrees to Oncogenex' proposed amendment to Phase 3 AFFINITY protocol

BerGenBio begins BGB324 Phase 1b trial in combination with erlotinib in NSCLC patients

Researchers identify immune system marker that drives therapy-resistant prostate cancer

Bringing real-time analytics to downstream bioprocess monitoring

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Latest News